FDA gives a nod to the new Neurostar Transcranial Magnetic Stimulation Therapy device for Depression

Depression, we all have gone through it at some point in our life and also overcome it. But there are people who experience extended duration of depression. Major depressive disorder results when the individual experiences isolation, despair, and devastating feeling of sadness that persist for at least 2 weeks or more. It is not the sporadic feeling of being lonely or sad that most individuals experience from time to time. Rather, an individual feels like he/she has fallen into a dark, deep hole with no scope of getting out of it.

The people suffering from major depressive disorder may have tried medications but, in some cases, it may not work. If you are looking for a solution, then this device may help you out. NeuroStar Advanced Therapy transcranial magnetic stimulation (TMS) system by Neuronetics has been cleared by the Food and Drug Administration (FDA) people with the treatment-resistant major depressive disorder. It is said to the only FDA-permitted TMS therapy that can be administered in less than 19 minutes. However, the time may differ depending on the recommendation of the physician.

The next-generation NeuroStar device is developed to benefit both the patients as well as physicians, with enhanced scheduling flexibility and ease for patients who require to adjust everyday treatment into their hectic schedules, and doctors seeking to offer treatment to a rising patient population.

The NeuroStar TMS device was first granted in 2008 by the FDA for the drug-resistant major depressive disorder. It was illustrated to be an efficient and safe therapy for individuals with major depressive disorder who did not benefit with at least one antidepressant.

The new NeuroStar Advanced Therapy provides numerous innovative and unique capabilities in comparison to the generic TMS systems, including 3D Laser Positioning, Contact Sensing, and High-Performance Coil. These revolutionary technology features offer the physicians with instantaneous feedback and provide consistent and unswerving treatment. The device has demonstrated efficiency across a wide array of treatment resistance. Around 58% of study participants notably responded to the therapy and also 37% attained complete remission of their signs of depression in the conducted clinical study.

If medication is not working for you, then maybe this device can be a solution.